These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 23560093)

  • 1. Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
    Oaks AW; Frankfurt M; Finkelstein DI; Sidhu A
    PLoS One; 2013; 8(4):e60378. PubMed ID: 23560093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in the nigrostriatal system following conditional inactivation of α-synuclein in neurons of adult and aging mice.
    Ninkina N; Tarasova TV; Chaprov KD; Roman AY; Kukharsky MS; Kolik LG; Ovchinnikov R; Ustyugov AA; Durnev AD; Buchman VL
    Neurobiol Aging; 2020 Jul; 91():76-87. PubMed ID: 32224067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP.
    Kurz A; May C; Schmidt O; Müller T; Stephan C; Meyer HE; Gispert S; Auburger G; Marcus K
    J Neural Transm (Vienna); 2012 Mar; 119(3):297-312. PubMed ID: 21960009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
    Lu XH; Fleming SM; Meurers B; Ackerson LC; Mortazavi F; Lo V; Hernandez D; Sulzer D; Jackson GR; Maidment NT; Chesselet MF; Yang XW
    J Neurosci; 2009 Feb; 29(7):1962-76. PubMed ID: 19228951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic DNA levels of mutant alpha-synuclein correlate with non-motor symptoms in an A53T Parkinson's disease mouse model.
    Wang W; Song N; Jia F; Tang T; Bao W; Zuo C; Xie J; Jiang H
    Neurochem Int; 2018 Mar; 114():71-79. PubMed ID: 29355568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine.
    Brehm N; Bez F; Carlsson T; Kern B; Gispert S; Auburger G; Cenci MA
    Mol Neurobiol; 2015 Dec; 52(3):1152-1164. PubMed ID: 25307288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease.
    Bellucci A; Navarria L; Falarti E; Zaltieri M; Bono F; Collo G; Spillantini MG; Missale C; Spano P
    PLoS One; 2011; 6(12):e27959. PubMed ID: 22163275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.
    Unger EL; Eve DJ; Perez XA; Reichenbach DK; Xu Y; Lee MK; Andrews AM
    Neurobiol Dis; 2006 Feb; 21(2):431-43. PubMed ID: 16230020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.
    Al-Wandi A; Ninkina N; Millership S; Williamson SJ; Jones PA; Buchman VL
    Neurobiol Aging; 2010 May; 31(5):796-804. PubMed ID: 19097673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit.
    Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P
    Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein.
    Lam HA; Wu N; Cely I; Kelly RL; Hean S; Richter F; Magen I; Cepeda C; Ackerson LC; Walwyn W; Masliah E; Chesselet MF; Levine MS; Maidment NT
    J Neurosci Res; 2011 Jul; 89(7):1091-102. PubMed ID: 21488084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effects of osmotin in Parkinson's disease-associated pathology via the AdipoR1/MAPK/AMPK/mTOR signaling pathways.
    Park JS; Choe K; Lee HJ; Park TJ; Kim MO
    J Biomed Sci; 2023 Aug; 30(1):66. PubMed ID: 37568205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tauopathic changes in the striatum of A53T α-synuclein mutant mouse model of Parkinson's disease.
    Wills J; Credle J; Haggerty T; Lee JH; Oaks AW; Sidhu A
    PLoS One; 2011 Mar; 6(3):e17953. PubMed ID: 21445308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
    Alarcón-Arís D; Recasens A; Galofré M; Carballo-Carbajal I; Zacchi N; Ruiz-Bronchal E; Pavia-Collado R; Chica R; Ferrés-Coy A; Santos M; Revilla R; Montefeltro A; Fariñas I; Artigas F; Vila M; Bortolozzi A
    Mol Ther; 2018 Feb; 26(2):550-567. PubMed ID: 29273501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.